GrpE like 1, mitochondrialGenealiases: GrpE · HMGE · mt-GrpE#1
Q-omics provides the consensus-scored GRPEL1 profile across patient tissues and cancer cell-line models. GRPEL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRPEL1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, GRPEL1 protein abundance shows 22,112 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, THCA, and LUAD as cancer lineages where GRPEL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRPEL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRPEL1 survival associations across molecular data types. GRPEL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRPEL1 RNA expression–survival associations across cancer types. High GRPEL1 expression shows unfavorable associations in HNSC, KICH, LUAD, UVM and LUSC, but favorable associations in READ. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GRPEL1 RNA expression.
This table summarizes GRPEL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GRPEL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRPEL1 shows lower tumor expression in THCA and KIRP and higher tumor expression in STAD, COAD, HNSC and LUSC. The THCA box plot shows higher GRPEL1 RNA expression in normal versus tumor tissue (log2 FC = −0.541, t-test p < 0.001).
This table shows molecular features associated with GRPEL1 in patient tissues and cancer cell lines. In patient samples, GRPEL1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GRPEL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
